Canopy Growth stock analysis
Canopy Growth (CGC) Stock Price & Analysis
CGC Stock Chart & Stats
- Day’s Range
- $0.50 - $0.54
- 52-Week Range
- $0.50 - $2.38
- Previous Close
- $0.53
- Volume
- N/A
- Average Volume (3M)
- 2.82M
- Market Cap
- $241.48M
- Enterprise Value
- $494.26M
- Total Cash (Recent Filing)
- $319.79M
- Total Debt (Recent Filing)
- $281.44M
- Price to Earnings (P/E)
- ―
- Beta
- 1.41
- Next Earnings
- Feb 05, 2027 (Est.)
- EPS Estimate
- -0.04
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Broad Revenue Growth
Broad-based revenue growth indicates improving demand across Canopy’s operating portfolio rather than reliance on one product or market. Continued gains in cannabis, medical, adult-use, and international channels could improve scale, strengthen brand reach, and support operating leverage over the next several quarters.
European Market Expansion
End-to-end EU GMP certification creates a durable platform for supplying regulated European markets and broadening beyond flower into additional patient-ready formats. This supports compliance, market access, product diversification, and potentially more consistent international growth as distribution expands.
Liquidity And Synergies
Substantial liquidity gives Canopy time to fund operations and execute cultivation, manufacturing, and distribution improvements while reducing immediate financing pressure. The targeted MTL synergies could also lower the cost base and improve earnings quality if delivered within the planned timeframe.
Bears Say
Persistent Losses And Cash Burn
Deep operating losses and negative operating and free cash flow show that the business is not yet self-funding. Continued cash consumption can constrain investment, increase reliance on available liquidity, and make the transition to sustainable profitability dependent on successful execution of planned improvements.
Gross Margin Pressure
The reimbursement-rate reduction directly pressured consolidated gross margin and demonstrates how policy-linked pricing can affect profitability in the medical channel. Unless pricing, mix, or operating efficiency offsets the impact, lower margins could limit conversion of revenue growth into durable earnings.
High Cultivation Costs
A structurally higher cultivation cost position can weaken competitiveness in a market where pricing and product affordability influence demand. Canopy’s strategy relies on higher-quality flower and better asset utilization, but those benefits must offset the cost disadvantage to support lasting margin improvement.
Canopy Growth News
CGC FAQ
What was Canopy Growth’s price range in the past 12 months?
What is Canopy Growth’s market cap?
When is Canopy Growth’s upcoming earnings report date?
How were Canopy Growth’s earnings last quarter?
Is Canopy Growth overvalued?
Does Canopy Growth pay dividends?
What is Canopy Growth’s EPS estimate?
How many shares outstanding does Canopy Growth have?
What happened to Canopy Growth’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Canopy Growth?
What is the TipRanks Smart Score and how is it calculated?
Canopy Growth Stock Smart Score
Company Description
Canopy Growth
Canopy Growth Corporation, through its various operating units, is actively involved in the cultivation, marketing, and distribution of cannabis and hemp-derived products. These offerings serve both recreational consumers and medical patients across key markets including Canada, the United States, and Germany. The company's business activities are structured into two main divisions: its global cannabis operations and its diverse portfolio of other consumer goods. Its extensive product line features dried cannabis flower, a variety of extracts and concentrates, beverages, edible gummies, and vaporization products. Canopy Growth commercializes these goods under numerous well-known brands such as Tweed, 7ACRES, 7ACRES Craft Collective, DOJA, Ace Valley, Quatreau, Deep Space, First + Free, Surity Pro, Spectrum Therapeutics, Vert, Tokyo Smoke, Twd, Martha Stewart CBD, DNA Genetics, BioSteel, Storz & Bickel, This Works, HiWay, Simple Stash, Whisl, and Truverra. Formed in 2009, the enterprise initially operated as Tweed Marijuana Inc. before adopting its current name, Canopy Growth Corporation, in September 2015. Its principal office is located in Smiths Falls, Canada.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- CEO
- Luc Mongeau
- Employees
- 1,128
- Website
- www.canopygrowth.com
- Address
- 1 Hershey Drive, Smiths Falls, ON, K7A 0A8, CA
Canopy Growth (CGC) Earnings & Revenues
CGC Earnings Call
Earnings Call SentimentPositive
The call was predominantly positive. Canopy reported strong consolidated, cannabis, international, medical, and adult-use revenue growth; improved operating efficiency; a narrower adjusted EBITDA loss; substantial liquidity; and progress in cultivation, EU GMP certification, and international expansion. The main negative factors were the 44% decline in Storz & Bickel revenue, lower consolidated gross margin due primarily to the Veteran Affairs Canada reimbursement-rate reduction, ongoing negative adjusted EBITDA, and the company's acknowledgment that cultivation costs are not yet best in class. Management nevertheless expressed confidence in achieving positive adjusted EBITDA in the second half of fiscal 2027 and in realizing further benefits from cultivation and operating initiatives.
View all CGC earnings summariesCGC Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 6 | 2 | 14 |
| Technical Analysis | 6 | 2 | 2 |
| Moving Averages | 0 | 0 | 12 |













